Catalent Micron Technologies - Enhanced bioavailability
Catalent provides end-to-end solutions to accelerate drug development programmes and with the addition of Micron Technologies’ particle size engineering capabilities, now has the broadest bioavailability solutions toolkit in the industry.
Catalent Micron Technologies - Enhanced bioavailability.Proven Results.
With the addition of Micron Technologies’ particle-size engineering expertise and experience, Catalent can support clients at the earliest stages of the drug development process, and provide end-to-end solutions to accelerate programmes to the clinic and market with the broadest bioavailability solutions toolkit in the industry. Micronization has many benefits, and is typically the first choice technology to improve the solubility performance of the product:
- Proven history
- Versatility (works on wide range of compounds)
- Broad acceptance (well understood by regulatory authorities)
- Scalable process
- Maximum efficiency (consistently produces high yields)
- Heat-free process (reduces risk of degradation)
Catalent Micron Technologies is the leading global provider for the most complex, specialised requirements in micronization, with the expertise to handle your toughest specifications. Micronization is used across most solid oral dosage types and inhalation delivery technologies to address increasing drug performance challenges.
Capabilities in particle size engineering include:
- Micronization
- Mechanical milling
- Cryogenic milling
- Highly potent and cytotoxic compounds
- Comprehensive analytical services
more products. better treatments. reliably supplied.™
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
